Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: tucatinib or placebo plus T-DM1 in HER2-positive unresectable locally advanced or metastatic breast cancer
2019-005017-39Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tukysa + ado-trastuzumab emtansine with Placebo + ado-trastuzumab emtansine (2 arms). Primary endpoint: Progression-free survival (PFS) by investigator assessment per RECIST v1.1. Started Jul 2020; status: active.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-005017-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-005017-39.